Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Data also demonstrated that none of the biological drugs selected for the comparison study proved to be anti-proliferative to any of the primary cell types assessed. Media Contact: Will Johnson. 646) 421-9523. 201-465-8019.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Veriheal

AUGUST 12, 2021

Patients who suffer from epilepsy , which affects some 3.4 Pharmaceutical CBD is currently a restricted prescription medication, and insurance coverage is often limited to only those patients with the specific approved indications. Researchers Analyzed Survey Results from 280 Epilepsy Patients.

Epilepsy 66

Epilepsy Pharmaceutical Patients Sleep 66

United Patients Group

JANUARY 4, 2024

As we move forward into 2024 and beyond, the sector offers diverse paths beyond direct patient care. The growth stems from rising healthcare demand, facility expansion, and the imperative for efficient administration to maintain quality patient care. Adverse drug events (ADEs) affect approximately 7 per 100 hospitalized patients.

Research and Development 52

Research and Development Patients Data Policy 52

SpeedWeed

JUNE 2, 2021

Data from Marijuana Business Daily’s 2021 Annual Marijuana Business Factbook puts the growth potential of the cannabis industry over the next several years into perspective. According to the data in the 2021 Annual Marijuana Business Factbook , U.S. Cannabis Sales Growth. cannabis sales will climb to $48.4 View original article.

Data 40

Data Media Business Cannabis 40

Illinois News Joint

JANUARY 30, 2023

The new website includes dropdown menus for information about CROO Media , Research and Data , Legal and Enforcement , About , and Agencies. The Media information includes Press Releases, Newsletters, Reports and Public Presentations, and Upcoming Dates. For more Illinois cannabis industry news, visit here.

Media 83

Media Data Agriculture Recreational 83

Cannabis Law Report

AUGUST 3, 2021

Unlike most other ailments, there isn’t a simple test that physicians can use to diagnose a patient with a disorder. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. (CSE: Source: Data Bridge.

Research and Development 105

Research and Development Data Conditions Therapy 105

Illinois News Joint

DECEMBER 18, 2023

From medical patients to MSOs, News Joint Consulting connects clients to cannabis insiders across the industry, including academics, municipalities, politicians, associations, event planners, conference organizers, vendors, new business owners, cultivators, breeders, brands, influencers, and more.

Events 95

Events Media Patients Data 95

Cannabis Law Report

AUGUST 2, 2021

The lab was born to fulfill an unmatched need in the industry to deliver a reliable, scientifically based standard methodology to allow patients to control their individual dose and overall predictability of a product’s intended therapeutic effects. “We Media Contact: Shawna Hassett, shassett@duffyshanley.com.

Hemp 105

Hemp Data Cultivation Patients 105

Cannabis Law Report

SEPTEMBER 15, 2019

The full media report dated 30 August 2019 can be found at. According to a media report , the German government took almost 13.3 These data are based on an extrapolation of the top pharmacist association. At the end of 2020, cannabis from German cultivation should be available for patients. ( Leafly.de reported. ).

Media 45

Media Medicine Collective Data 45

SpeedWeed

JULY 25, 2021

Here are the applicants and their scores with notable MSO losses in red text: Copyright © 2021 by CNB Media LLC dba Cannabiz Media Source: Cannabiz Media License Database www.cannabiz.media. Copyright © 2021 by CNB Media LLC dba Cannabiz Media Source: Cannabiz Media License Database www.cannabiz.media.

Media 52

Media Data Dispensary Access 52

SpeedWeed

MARCH 17, 2021

Deal size aside, we wanted to share what we look at on the data side when a public company or MSO announces a deal. Today, Curaleaf LLC is one of four licensed growers in Connecticut and operates a 60,000 square foot cultivation facility in Simsbury that provides cannabis products to over 40,000 patients throughout the state.

Media 52

Media Data Dispensary Cultivation 52

MMJ Recs

MAY 3, 2024

With its program in full swing, thousands of patients across the state are benefiting from access to this alternative form of treatment. From chronic pain to PTSD, patients with qualifying medical conditions have found solace in medical marijuana where traditional treatments may have fallen short.

Marijuana 52

Marijuana Treatment Compliance Compliance 52

Cannabis Law Report

MARCH 3, 2022

Former President Bill Clinton has apparently been hearing a lot about the therapeutic potential of CBD products for pain management lately, and, according to a now-deleted media report, said at a recent conference appearance that broad interest in the topic should spur regulators to develop standards for the cannabinoid. Ganjapreneur report.

Media 52

Media CBD Events THC 52

Cannabis Law Report

AUGUST 27, 2021

The Board will further serve as a resource for media, other medical associates and general audiences interested in the science behind psychedelic wellness and treatments. Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation.

Research and Development 98

Research and Development Treatment Media Medicine 98

Cannabis Law Report

DECEMBER 27, 2019

A Windsor, Ontario-based company Audacia Bioscience is especially focussed on three patented technologies that deliver consumer and patient insights to the industry to close the knowledge gaps in the supply chain. Cognizance VCT enables the generation of cost-effective quality data with ethical consent, on par with academic studies.

Clinical Trials 85

Clinical Trials Access Research and Development Supply Chain 85

Cannabis Law Report

NOVEMBER 23, 2021

London, UK – 23 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office. PRESS RELEASE. ” About COMPASS Pathways.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

JUNE 30, 2021

Despite the high prevalence of these disorders, few patients are accurately screened and diagnosed. of patients with major depressive disorder, 92.7% of patients with bipolar disorder, 71% of patients with generalized anxiety disorder, and 97.8% of patients with social anxiety disorder. Building the Data Backend.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. COMP360 psilocybin therapy has now been given to 233 patients, exceeding 216 target. On track to report top-line data by end of 2021. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JULY 6, 2021

Professor Johnson also received national media attention for his appearance in the Home Box Office (HBO) original documentary feature, “Addiction”, which won the prestigious Governors Award, a special Emmy Award, from the Academy of Television Arts and Sciences. Ehave, Inc. Forward-Looking Statement Disclaimer.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. Of the 22 patients, 19 experienced adverse events after ingesting delta-8 THC-containing food products (e.g.,

THC 105

THC Pets Events Hemp 105

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients. The cannabis research problem. There’s another problem: science communication and literacy.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Illinois News Joint

MAY 27, 2023

With the immense popularity of Kaviar spawning in such a short time, the team invested heavily in marketing at industry events, interacting with customers directly at dispensaries, and cultivating an engaging following on social media. To qualify and receive a medical patient card at a discounted rate, visit here.

Terpenes 82

Terpenes Strains Dispensary Events 82

Cannabis Law Report

OCTOBER 15, 2021

The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., DNA variations or polymorphisms) in patients with African ancestry. Poster Number: INFO37. Poster Number: PO1326.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

JULY 9, 2021

The medical use of certain psychedelic drugs and substances remain illegal under Canadian federal law unless discretionary exemptions are granted under the CDSA, while a limited number of other drugs and substances may be prescribed by a health care practitioner to patients under their care. SOURCE Horizons ETFs Management ( Canada ) Inc.

Data 105

Data Clinical Trials Decriminalization Hemp 105

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. In 2022, we anticipate reading out interim data from our ongoing Phase 2 clinical trial of GFB-887, as well as initial data from our ongoing Phase 1 study of GFB-024.

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

SEPTEMBER 20, 2021

KWC and KIC have been focused on opening locations in Secondary cities with considerable demand, in an effort to provide access to the most patients. Adding KWC will ensure our existing patients and many more in the future will receive the best medical treatment and care.

Treatment 52

Treatment Media Research and Development Patients 52

CannaMD

NOVEMBER 6, 2019

Today, both patient experience and modern scientific research support claims of medical marijuana’s effectiveness for pain management. Questions included any changes in personal levels of opioid use when marijuana was also used, and the reasons why patients were substituting marijuana for prescription pain medications.

Marijuana 87

Marijuana Patients Clinical Trials Data 87

The Cannigma

OCTOBER 22, 2023

The Cannigma has always taken a data-informed approach to content creation – though up until recently we’ve been primarily leaning on the existing peer-reviewed literature to guide our content. We need more data – human data – on specific applications for the plant – symptoms, use cases, conditions and patient types.

Data 88

Data Research and Development Sleep Collective 88

Cannabis Law Report

NOVEMBER 22, 2019

“Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. MMJ is confident that their pharmaceutical drugs will bring much needed relief to patients suffering from the debilitating effects of Multiple Sclerosis and Huntington’s Disease. For media inquiries please contact: Michael Sharp.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

OCTOBER 22, 2021

–The Company expects to hold a Research & Development event to review,these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media– TORONTO, CANADA – October 19, 2021 – Cybin Inc.

Research and Development 52

Research and Development Safety Media Data 52

Cannabis Law Report

JULY 22, 2021

. “By acquiring traditional healthcare assets and subsequently layering in alternative medicines and psychedelic therapies as regulations develop, Levitee will have direct and immediate access to a much broader patient population. Levitee Media Contact. media@leviteelabs.com. The CSE (operated by CNSX Markets Inc.)

eCommerce 105

eCommerce Therapy Media Access 105

Cannabis Law Report

DECEMBER 26, 2021

. “With the filing of our provisional patent application, Entheon is building an IP foundation to better facilitate safe and precise use of psychedelics to deliver improved patient outcomes.” For media inquiries, please contact Elizabeth Glassen of BlueSky Communications at: BlueSky Communications.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

NOVEMBER 9, 2021

Delic has been focused on opening locations in secondary cities with considerable demand, in an effort to provide access to the most patients. Delic expects to drive considerable patients to KWC through its media platform and build on the existing national leadership position already in place. Transaction Summary.

Treatment 52

Treatment Therapy Media Access 52

Cannabis Law Report

JULY 29, 2021

There have been various individual studies of the condition, but the Ehave study could be the largest patient study to date. EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Media Inquiries: Gabe Rodriguez. Forward-Looking Statement Disclaimer. Contact: Ehave Inc.

Research and Development 105

Research and Development Conditions Data Patients 105

Cannabis Law Report

JUNE 16, 2021

Genetic Screening Platform Technology and Data to Strengthen Entheon’s Psychedelic-Assisted Protocols. Lobo brings a highly experienced and specialized team of technology experts in the fields of genetics, diagnostics, data and analytics, as well as a fully operational 5,000 sq. Vancouver, British Columbia–(Newsfile Corp.

Research and Development 105

Research and Development Data Conditions Events 105

Cannabis Law Report

DECEMBER 14, 2021

The products launched under its flagship medical Ceed brand and are comprised of four formulations that will be available for patients throughout the UK when prescribed by a specialist consultant. Columbia Care’s mission has always been to provide patients with access to the highest quality, safest medicinal cannabis products available.

Extraction 52

Extraction Patients Medicine Tincture 52

CannaMD

MAY 19, 2020

Our initial data suggest that some C. Note: Study extracts were applied via media. CannaMD will continue to keep patients updated as more information becomes available. But what does marijuana have to do with ACE2? Our results lay a foundation for further in-depth analysis of the effects of C. Find a Medical Marijuana Doctor.

Research and Development 131

Research and Development Sativa Marijuana Extraction 131